{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T12:05:00Z","timestamp":1772366700638,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Cancer Institute, National Institutes of Health, and The Beatrice and Samuel A. Seaver Foundation for Cancer and Aging","award":["P01 CA23766"],"award-info":[{"award-number":["P01 CA23766"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bbmt.2017.06.024","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T12:32:14Z","timestamp":1500467534000},"page":"1685-1694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies"],"prefix":"10.1016","volume":"23","author":[{"given":"Ann A.","family":"Jakubowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Petrlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Maloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Hilden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Boulad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Castro-Malaspina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenther","family":"Koehne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.06.024_bib0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/sj.bmt.1705119","article-title":"Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts","volume":"36","author":"Novitzky","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0015","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood.V89.8.3039","article-title":"CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission","volume":"89","author":"Soiffer","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0020","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood.V91.3.1083","article-title":"T- cell\u2013depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease","volume":"91","author":"Papadopoulos","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0025","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2007-06-093880","article-title":"T cell\u2013 depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin","volume":"110","author":"Jakubowski","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbmt.2011.01.005","article-title":"T cell\u2013 depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies","volume":"17","author":"Jakubowski","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0035","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbmt.2012.09.003","article-title":"T cell\u2013depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease","volume":"19","author":"Goldberg","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0040","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bbmt.2015.07.010","article-title":"CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse","volume":"21","author":"Tamari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0045","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bbmt.2013.02.018","article-title":"Ex vivo T cell\u2013 depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/bmt.2014.302","article-title":"Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts","volume":"50","author":"Hobbs","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0055","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0060","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0065","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0070","doi-asserted-by":"crossref","first-page":"2991a","DOI":"10.1182\/blood.V110.11.2991.2991","article-title":"Phase II trial of a chemotherapy-only regimen of busulfan, melphalan, fludarabine and R-ATG followed by allogeneic T-cell depleted hematopoietic stem cell transplants for the treatment of myeloid malignancies","volume":"supplement","author":"Boulad","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0140-6736(81)90647-4","article-title":"Transplantation for acute leukemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells","volume":"2","author":"Reisner","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0080","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbmt.2011.08.017","article-title":"Characteristics of CliniMACS\u00ae system CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303","volume":"18","author":"Keever-Taylor","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0085","first-page":"223","article-title":"Comparison of bone marrow and G-CSF mobilized peripheral blood progenitor cells from single normal donors before and after T cell depletion","volume":"1","author":"Collins","year":"1999","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0090","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0100","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","article-title":"A scheme for defining cause of death and its application in the T cell depletion trial","volume":"13","author":"Copelan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0105","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.bbmt.2011.02.007","article-title":"Myeloablative reduced- toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life","volume":"17","author":"Alatrash","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0110","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.bbmt.2009.12.537","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age","volume":"16","author":"Koreth","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbmt.2010.02.004","article-title":"Prognostic factor and quality of life analysis in 160 patients aged \u226560 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation","volume":"16","author":"Deschler","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0120","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0125","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0130","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/bmt.2010.227","article-title":"Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT","volume":"46","author":"Castagna","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0135","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.bbmt.2005.06.006","article-title":"Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older","volume":"11","author":"Gupta","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0140","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/bmt.2010.164","article-title":"Impact of intensity of conditioning therapy in patients aged 40-60 years with AML\/myelodysplastic syndrome undergoing allogeneic transplantation","volume":"46","author":"Khabori","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbmt.2011.07.013","article-title":"Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC","volume":"18","author":"Chevallier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0150","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bbmt.2010.02.006","article-title":"Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell depleted hematopoietic stem cell transplantation","volume":"16","author":"Glezerman","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bmt.1704518","article-title":"Allogeneic myeloablative transplantation for patients aged 50 years and over","volume":"34","author":"Yanada","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0160","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0165","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0170","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1086\/342332","article-title":"Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors","volume":"35","author":"Meijer","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00007890-200207150-00009","article-title":"Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation","volume":"74","author":"Lin","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1399-3062.2007.00235.x","article-title":"Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Almyroudis","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0185","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.V93.2.467","article-title":"Comparison of immune reconstitution after unrelated and related T-cell\u2013depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions","volume":"93","author":"Small","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0190","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.leu.2403055","article-title":"Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia","volume":"17","author":"Kumar","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0195","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bmt.1705648","article-title":"Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients","volume":"39","author":"Heining","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0200","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bbmt.2010.11.020","article-title":"Lymphocyte recovery predicts outcomes in cord blood and T cell\u2013depleted haploidentical stem cell transplantation","volume":"17","author":"Ciurea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.12338","article-title":"Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts","volume":"93","author":"Michelis","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0210","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/bmt.2012.211","article-title":"Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning","volume":"48","author":"DeCook","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0215","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbmt.2007.07.005","article-title":"Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell- depleted allogeneic stem cell transplantation","volume":"13","author":"Savani","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/bmt.2016.201","article-title":"Sixty as the new forty: considerations on older related stem cell donors","volume":"52","author":"Anderlini","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0225","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/leu.2012.210","article-title":"Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings","volume":"27","author":"Kroger","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0230","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.bmt.1705388","article-title":"Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?","volume":"38","author":"Mehta","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0235","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bbmt.2008.02.006","article-title":"Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA- identical siblings","volume":"14","author":"Castro-Malaspina","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0240","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2012.41.7071","volume":"30","author":"Pasquini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0245","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bbmt.2013.06.008","article-title":"Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"19","author":"Brunner","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0250","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bmt.2013.67","article-title":"To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century","volume":"48","author":"Ustun","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"S2","key":"10.1016\/j.bbmt.2017.06.024_bib0255","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/bmt.2015.87","article-title":"Improved immune recovery after transplantation of TCR[alpha][beta]\/CD19-depleted allografts from haploidentical donors in pediatric patients","volume":"50","author":"Lang","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0260","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jcyt.2013.05.014","article-title":"Depletion of T-cell receptor alpha\/beta and CD19 positive cells from apheresis products with the CliniMACS device","volume":"15","author":"Schumm","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0265","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bmt.2015.343","article-title":"TCR- alpha\/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia","volume":"51","author":"Maschan","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0270","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2012-06-437236","article-title":"Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation","volume":"120","author":"Perales","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.06.024_bib0275","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.beha.2015.10.009","article-title":"Is there a role for therapy after transplant?","volume":"28","author":"Oran","year":"2015","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117305554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117305554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:59:22Z","timestamp":1761058762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117305554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1083879117305554"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.06.024","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}